Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial
Key Takeaways
- Ozempic is FDA-approved only for adults with type 2 diabetes; weight loss is not on the label
- Off-label prescribing for weight loss is legal but is rarely covered by insurance and depends on prescriber judgment
- Wegovy (semaglutide under a different brand) is the FDA-approved path for non-diabetic patients with BMI 30+ or 27+ with a comorbidity
- Telehealth has expanded access through compounded semaglutide via 503A pharmacies, with state-level variation in legality and oversight
- Several patient groups are flatly excluded: personal or family MTC, MEN-2, pregnancy, prior pancreatitis, and severe gastroparesis
Direct answer
No, not anyone can get Ozempic. The drug is FDA-approved only for adults with type 2 diabetes. People without diabetes sometimes obtain Ozempic through off-label prescribing for weight loss, but insurance rarely covers it and many telehealth platforms route those patients to Wegovy or compounded semaglutide instead. Patients with a history of medullary thyroid cancer, MEN-2, pregnancy, prior pancreatitis, or severe gastroparesis are typically excluded regardless of insurance or pathway.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The FDA label, in plain language
- What "off-label" actually means
- Wegovy vs. Ozempic: same drug, different doors
- The telehealth path
- The compounded path
- Who is excluded by safety criteria
- State-by-state variation
- The cash-pay reality
- Contrary view: should access be wider
- Decision framework
- FAQ
- Sources
The FDA label, in plain language
Ozempic (semaglutide injection, 0.25 mg to 2 mg weekly) was approved by the FDA in December 2017 for one indication: improving glycemic control in adults with type 2 diabetes mellitus. A 2020 supplemental approval added reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Weight loss is not on the label. It appears in clinical trials as a secondary outcome and in the prescribing information as an expected effect, but the FDA has not approved Ozempic for the treatment of obesity. That distinction matters for insurance coverage, prescriber liability, and pharmacy stocking decisions.
What "off-label" actually means
Off-label prescribing is legal in the United States. A licensed clinician can prescribe an approved drug for a use the FDA has not specifically reviewed, provided there is reasonable medical evidence and the patient gives informed consent. The FDA regulates manufacturer marketing, not physician judgment.
For Ozempic specifically, off-label use for weight loss in non-diabetic patients has been common since 2021. The evidence base from STEP 1 (Wilding et al. 2021, NEJM) showing mean weight loss of approximately 14.9% in non-diabetic adults at 2.4 mg dosing supports the off-label use. The catch: Ozempic only goes up to 2 mg, so even off-label users are receiving a lower dose than the obesity-focused trials studied.
Insurance coverage almost never follows off-label prescribing for Ozempic. Most commercial plans require an HbA1c result consistent with type 2 diabetes before approving the prescription. Patients without diabetes who get an off-label prescription typically pay cash (roughly $1,000 to $1,200 per month at brand pricing) or go without.
Wegovy vs. Ozempic: same drug, different doors
Semaglutide is the same molecule regardless of brand. Novo Nordisk markets it as Ozempic for diabetes and Wegovy for obesity, with the only practical differences being the dose ceiling (Ozempic 2 mg, Wegovy 2.4 mg) and the labeled indication.
For non-diabetic patients seeking semaglutide for weight loss, Wegovy is the correct prescription. It is FDA-approved for adults with BMI 30+ or BMI 27+ with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease). The 2023 SELECT trial added a cardiovascular benefit indication for adults with established cardiovascular disease and overweight or obesity.
Insurance coverage for Wegovy is more common than for off-label Ozempic, though still inconsistent. Some plans cover it as a weight-loss medication; others exclude all weight-loss pharmacotherapy categorically.
The telehealth path
Telehealth GLP-1 prescribing expanded rapidly after 2021. The structure is consistent across reputable platforms:
- Patient completes an intake form covering medical history, current medications, contraindications
- A clinician licensed in the patient's state reviews the file and either approves, requests more information, or declines
- If approved, the prescription routes to a partnered pharmacy, often a 503A compounding pharmacy preparing compounded semaglutide
- Medication ships to the patient with dosing instructions and ongoing clinical support
The legal requirement is a bona fide patient-provider relationship in the prescribing state. Some states require synchronous video evaluation; others accept asynchronous review. Patients should verify that the prescriber holds an active license in their state and that the pharmacy is properly registered.
The compounded path
503A compounding pharmacies prepare medications in response to individual prescriptions for specific patients. During the FDA-declared shortage of semaglutide (December 2022 through October 2024) and tirzepatide (December 2022 through October 2024), 503A pharmacies were permitted to compound copies of these molecules under section 503A of the Federal Food, Drug, and Cosmetic Act.
The shortage status changed in late 2024. The FDA declared the semaglutide shortage resolved in February 2025 and tirzepatide resolved in October 2024. Compounding is now more restricted: pharmacies generally must demonstrate clinical necessity (allergy to an inactive ingredient, dosing requirement not met by commercial product) or fall under separate state-level compounding provisions.
FormBlends works with state-licensed 503A pharmacies and clinicians who document medical necessity. Compounded semaglutide is not FDA-approved and is not interchangeable with brand Ozempic or Wegovy.
Who is excluded by safety criteria
These exclusions apply regardless of pathway (brand, off-label, compounded):
| Condition | Reason for exclusion |
|---|---|
| Personal or family history of medullary thyroid carcinoma | Boxed warning; rodent studies showed thyroid C-cell tumors |
| Multiple Endocrine Neoplasia syndrome type 2 | Boxed warning; increased thyroid cancer risk |
| Pregnancy | Animal data suggest fetal harm; discontinue at least 2 months before planned conception |
| Prior pancreatitis | Acute pancreatitis reported in trials; recurrence risk elevated |
| Severe gastroparesis | Drug delays gastric emptying further; symptomatic worsening likely |
| Severe hypersensitivity to semaglutide | Rare but reported; documented allergic reactions disqualify |
Relative cautions (not absolute exclusions) include diabetic retinopathy (acute glycemic shift may temporarily worsen retinopathy), eating disorder history, history of suicidal ideation, and active gallbladder disease.
State-by-state variation
Three areas vary by state:
Telehealth prescribing rules. Some states require synchronous video evaluation for first-time controlled substance prescriptions; semaglutide is not controlled, but state medical boards sometimes apply similar standards to GLP-1 medications. California, New York, and Texas have stricter documentation expectations than most.
Compounding scope. States regulate 503A pharmacies through their boards of pharmacy. A few states (notably Mississippi) have more permissive compounding rules; others (notably California) impose tighter restrictions.
Insurance benefit design. Medicaid coverage of obesity medications varies dramatically. Some state Medicaid programs cover Wegovy; others exclude all weight-loss drugs. Medicare currently does not cover any drug prescribed solely for weight loss, though the SELECT cardiovascular indication has changed coverage for some Wegovy prescriptions.
The cash-pay reality
Without insurance, brand Ozempic typically costs $1,000 to $1,200 per month at cash-pay pharmacy pricing in 2026. GoodRx and similar coupon programs can reduce this somewhat but rarely below $900. Manufacturer savings cards from Novo Nordisk require commercial insurance coverage to activate.
Compounded semaglutide through 503A pharmacies typically prices in the $200 to $500 per month range depending on dose, pharmacy, and platform. The price difference reflects the absence of FDA approval, brand premium, and the manufacturing scale of commercial vs. compounded preparations.
Lilly Direct, Eli Lilly's direct-to-consumer cash-pay program for Zepbound (tirzepatide), launched in 2024 at roughly $349 per month for 2.5 mg single-dose vials, scaling up for higher doses. This is a Zepbound program, not an Ozempic program, but it represents a manufacturer-led cash-pay path that has shifted the access landscape.
Contrary view: should access be wider
The strongest argument for broader access: GLP-1 medications appear to reduce all-cause mortality risk in obesity (SELECT trial 2023, NEJM), and obesity itself carries elevated risk for cardiovascular disease, type 2 diabetes, certain cancers, and premature death. Restricting access to those who meet narrow BMI cutoffs may exclude patients who would benefit.
The counter-argument: GLP-1 medications carry real risks (pancreatitis, gallbladder events, severe gastrointestinal side effects, possible thyroid cancer signal from animal data, lean mass loss). Prescribing to patients with marginal benefit dilutes the risk-benefit calculation. Wider access also amplifies supply pressure on patients with diabetes, where the medication has the longest track record.
The reasonable middle ground: clear FDA-approved pathways for documented obesity (BMI 30+ or BMI 27+ with comorbidity), off-label discretion for clinicians treating individual patients with documented metabolic risk, and stronger regulation of gray-market and counterfeit channels that exist precisely because legitimate access is constrained.
Decision framework
If you have type 2 diabetes: Ozempic is the on-label option. Insurance coverage is generally good. Discuss with your endocrinologist or primary care provider.
If you have BMI 30+ or 27+ with a comorbidity, no diabetes: Wegovy is the FDA-approved path. If insurance covers obesity medications, this is the cleanest route. If insurance does not cover Wegovy, compounded semaglutide through a 503A pharmacy is a documented alternative.
If you have BMI 25-27 and want GLP-1 for metabolic reasons: You are outside FDA-approved criteria. Some clinicians will prescribe off-label; many will not. The risk-benefit calculation at lower BMIs is less favorable.
If you have any boxed-warning contraindication: Do not pursue GLP-1 therapy regardless of pathway or platform.
If you are pregnant, trying to conceive, or breastfeeding: Discontinue or defer GLP-1 therapy and discuss alternatives with your prescriber.
FAQ
Can anyone get Ozempic? Not anyone. Ozempic is FDA-approved only for adults with type 2 diabetes. Non-diabetic patients sometimes obtain it through off-label prescribing, but insurance rarely covers off-label use and most reputable platforms route non-diabetic weight-loss patients to Wegovy or compounded semaglutide.
Can I get Ozempic if I do not have diabetes? Sometimes, through off-label prescribing. A licensed clinician can legally prescribe Ozempic for weight loss even though the FDA label does not list that use, but insurance will almost never cover it.
Can teenagers get Ozempic? Ozempic is approved only for adults. Wegovy is FDA-approved for adolescents 12 and older with BMI at or above the 95th percentile for age and sex (approval added June 2023).
Can I get Ozempic through telehealth? Yes, through a state-licensed telehealth provider after clinical evaluation. Telehealth platforms typically prescribe compounded semaglutide rather than brand Ozempic.
Who cannot take Ozempic? Patients with personal or family history of medullary thyroid carcinoma, MEN-2, pregnancy, prior pancreatitis, severe gastroparesis, or severe hypersensitivity to semaglutide.
Can someone with prediabetes get Ozempic? Not on label. The FDA approval is for type 2 diabetes. Some clinicians prescribe off-label for prediabetes patients who also meet weight criteria, but insurance coverage is rare.
Is buying Ozempic without a prescription legal? No. Ozempic is prescription-only. Buying from overseas pharmacies, gray-market sellers, or unverified online sources is illegal and unsafe.
Can I get Ozempic if I am thin? Not typically. Off-label prescribing for cosmetic weight loss in normal-BMI patients is broadly considered outside the standard of care.
Sources
- FDA. Ozempic Prescribing Information (semaglutide injection). Current label revision 2025.
- FDA. Wegovy Prescribing Information (semaglutide injection). Current label revision 2025.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023.
- FDA. Drug Shortages: Semaglutide Update, February 2025.
- FDA. Counterfeit Ozempic Found in U.S. Drug Supply Chain. Safety Communication, December 2023.
- American Association of Clinical Endocrinologists. Clinical Practice Guideline: Pharmacotherapy of Obesity. 2024.
- Endocrine Society. Clinical Practice Guideline: Pharmacological Management of Obesity. 2023 update.
- Centers for Medicare and Medicaid Services. National Coverage Determination Manual: Anti-Obesity Drugs. Updated 2025.
- State Boards of Pharmacy. 503A Compounding Regulations Survey. National Association of Boards of Pharmacy, 2025.
- Wegovy Pediatric Approval Letter. FDA, June 2023.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health company that connects patients with independent licensed clinicians and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. Eligibility for any treatment is determined by an independent provider after clinical evaluation.
Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed 503A pharmacy in response to an individual prescription. Compounded medications do not undergo the same premarket review as brand-name products and are not interchangeable with Ozempic or Wegovy.
Results Disclaimer. Weight-loss and glycemic outcomes vary by patient, baseline metabolic status, diet, exercise, and adherence. Trial percentages cited reflect average results in study populations and are not predictions of individual outcomes.
Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.